ClinicalTrials.gg
CompletedNCT02137239Updated Jun 22, 2021Results posted

Regimen Optimization Study

A Phase 2 interventional study of Thymoglobulin and Belatacept in Kidney Transplantation, sponsored by Bristol-Myers Squibb. Completed at 20 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-22.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit damage to or the possibility of rejecting the transplanted kidney. The purpose of this study is to evaluate benefits and risks of two immunosuppressive regimens (belatacept with everolimus or tacrolimus with mycophenolate mofetil) following thymoglobulin induction and rapid corticosteroid withdrawal.

Read the detailed description

Calcineurin inhibitor (CNI)

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Men and women, aged 18 to 75
  • Serologic test results are positive for past exposure to Epstein Barr Virus (EBV+)
  • Diagnosed with end stage renal disease (ESRD) and scheduled to undergo transplantation of a non-HLA identical, living or standard criteria deceased donor kidney

Exclusion criteria

Exclusion Criteria:

  • Primary cause of ESRD is: primary focal segmental glomerulosclerosis; or Type I or II membranoproliferative glomerulonephritis; or Hemolytic Uremic Syndrome / Thrombotic Thrombocytopenic Purpura
  • Had a previous graft loss due to acute rejection
  • At increased immunologic risk of graft loss due to panel reactive antibodies (PRA) >20% or need for desensitization therapy
  • Scheduled to receive a: kidney from identical twin; or paired kidney; or kidney from a Cytomegalovirus(CMV) positive donor when recipient is CMV negative; or kidney from an extended criteria donor
  • Have a (BMI) of > 35 kg/m2 for nondiabetics or > 30 kg/m2 for diabetics
  • Diagnosed as positive; or positive; or positive; or currently or previously active or inadequately treated latent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Belatacept + Everolimus

    Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)

    Drug: Thymoglobulin · Drug: Belatacept · Drug: Corticosteroids · Drug: Everolimus(EVL)

  • Experimental
    Tacrolimus + Mycophenolate mofetil

    Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)

    Drug: Thymoglobulin · Drug: mycophenolate mofetil(MMF) · Drug: Corticosteroids · Drug: Tacrolimus(TAC)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months

    Number of Participants with Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6 Months

    Time frame: 6 Months

Secondary outcomes

  1. Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6, 12 and 24 Months

    Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6, 12 and 24 Months Change in the incidence of CSBPAR at 6, 12 and 24 months post transplant, in the belatacept + EVL(Treatment A) as compared to TAC + MMF (Treatment B).

    Time frame: Up to 24 Months

  2. Time to Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR).

    Time to Clinically suspected biopsy proven acute rejection

    Time frame: Up to 24 Months

  3. Percentage of Participants With BANFF Grade by Severity Grades. BANFF Type (Grade) for Acute/Active Rejection

    Treatment differences in the severity grades to treat all episodes of CSBPAR at 6, 12, and 24 months post-transplant. Type 1A - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>4 mononuclear cells/Tubular cross section or group of 10 Tubular cell). Type 1B - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>10 mononuclear cells/Tubular cross section or group of 10 Tubular cell).Type 2A - Cases with mild to moderate intimal arteritis.Type 2B - Cases with severe intimal arteritis comprising \>25% of the luminal area. Type 3 - Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (v3 with accompanying lymphocytic inflammation)

    Time frame: At 6, 12 and 24 Months

  4. Treatment Differences in Therapeutic Modalities

    Treatment Received for Biopsy Proven Acute Rejection (Banff Grade IA or Higher), or Humoral (Antibody Mediated) Rejection Treatment regimen: Categorical analysis of CSBPAR episodes by treatment received.

    Time frame: at 6, 12 and 24 Months

  5. Number of Participants Who Survive With a Functioning Graft

    Number of all participants who survive with a functioning graft at 6, 12 and 24 months post transplant

    Time frame: At 6, 12 and 24 months

  6. Number of Participants Deaths Post Transplant

    Number of participant deaths at 6, 12 and 24 months post transplant

    Time frame: up to 24 months

  7. Number of Participants Who Experience Graft Loss Post Transplant

    Number of all participants who experience graft loss at 6, 12 and 24 months post transplant

    Time frame: At 6, 12 and 24 months

  8. Time to Event: Graft Loss and Death

    The Number of days to participant Graft Loss and death for any reason

    Time frame: Up to 728 Days

  9. Absolute Calculated Glomerular Filtration Rate (cGFR): Mean

    Absolute (mean and median) cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula

    Time frame: Up 24 Months post-transplant

  10. Median Calculated Glomerular Filtration Rate (cGFR)

    Median cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula

    Time frame: Up 24 Months post-transplant

  11. Mean Change From Month 3 in cGFR

    The mean change from Month 3 cGFR at 3, 6, 12 and 24 months post-transplant

    Time frame: Up 24 Months post-transplant

  12. Urine Protein Creatinine Ratio (UPr/Cr)

    Urine protein to creatinine ratio (UPr/Cr) at 3, 6, 12 and 24 months post-transplant.

    Time frame: Up 24 Months post-transplant

  13. Percentage of Participants With Donor Specific Anti-HLA Antibodies (DSA)

    Percentage of participants with, and titers of pre-existing (pre-transplant) DSA on Day 1 (pre-transplant, pre-dose), and at Months 12 and 24 posttransplant

    Time frame: Up to 24 Months

  14. Percentage of Participants With De Novo Donor Specific Anti-HLA Antibodies (DSA)

    Characterization of any de novo DSA detected by IgM and IgG subclasses, and by the presence or absence of complement fixing properties.

    Time frame: Up to 24 Months

  15. Percentage of Participants With Adverse Events (AEs)

    Percentage of participants with AEs up to 24 months post-transplant

    Time frame: Up to 24 months Post-Transplant

  16. Percentage of Participants With Serious Adverse Events (SAEs)

    Percentage of participants with SAEs up to 24 months post-transplant

    Time frame: Up to 24 months Post-Transplant

  17. Percentage of Participants With Events of Special Interest (ESIs)

    Percentage of participants which have one of the following events of special interest: Serious Infections Post-Transplant Lymphoproliferative Disorder (PTLD) Progressive multifocal leukoencephalopathy (PML) Malignancies (Other than PTLD) including non-melanoma skin carcinomas (Malignancies) Tuberculosis Infections Central Nervous System (CNS) Infections Viral Infections Infusion Related reactions within 24 hours since belatacept infusion

    Time frame: Up to 24 Months

  18. Percentage of Particpants With Laboratory Test Abnormalities (LTAs)

    Percentage of participants with laboratory tests with marked laboratory abnormalities

    Time frame: At 24 Months

  19. Mean and Mean Change From Baseline in Blood Glucose

    Mean fasting blood glucose levels, and mean changes from baseline values at Months 6, 12 and 24 months post- transplant

    Time frame: Up to 24 months

  20. Mean and Mean Change From Baseline in Whole Blood HbA1c

    Mean whole blood HbA1C concentrations, and mean changes from baseline values at Months 6, 12 and 24 months post-transplant.

    Time frame: Up to 24 months

  21. Percentage of Participants With New Onset Diabetes After Transplant

    Percentage of participants with New Onset Diabetes After Transplantation (NODAT) at 6, 12, and 24 months post-transplant.

    Time frame: up to 24 months

  22. Absolute Values of Blood Pressure: Mean

    Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;

    Time frame: Up to 24 Months

  23. Absolute Values of Blood Pressure: Median

    Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;

    Time frame: Up to 24 Months

  24. Mean Changes From Baseline Values for Blood Pressure

    Mean changes from baseline values for SBP and DBP at 6, 12 and 24 months post-transplant

    Time frame: Up to 24 Months

  25. Absolute Values of Fasting Lipid Values: Mean

    Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)

    Time frame: Up to 24 Months

  26. Absolute Values of Fasting Lipid Values: Median

    Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)

    Time frame: Up to 24 Months

  27. Mean Changes From Baseline Values of Lipid Values

    Mean changes from baseline values in the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)

    Time frame: at months 12 and 24

07

Results

Posted Jun 22, 2021
Limitations and caveats
One participant with BPAR had been randomized to the BELA+EVL group, but had then mistakenly been treated with TAC+MMF beginning on Day 1 and continuing through the entire 2-year study period. Due to this, time to CSBPAR was performed using this inaccurate population, therefore inaccurate data is not presented.

Participant flow

Participant flow — Overall Study
MilestoneTreatment ATreatment B
Started2632
Completed2326
Not completed36
Withdrew: Discontinued study treatment03
Withdrew: Withdrew consent11
Withdrew: Adverse event22

Outcome measures

PrimaryPercentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months

Number of Participants with Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6 Months

Time frame:
6 Months
Reported as:
Number · Percentage of participants
Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months
Percentage of participantsTreatment ATreatment B
Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months7.7 (0.9 to 25.1)9.4 (2.0 to 25.0)
SecondaryClinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6, 12 and 24 Months

Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6, 12 and 24 Months Change in the incidence of CSBPAR at 6, 12 and 24 months post transplant, in the belatacept + EVL(Treatment A) as compared to TAC + MMF (Treatment B).

Time frame:
Up to 24 Months
Reported as:
Number · Percentage of CSBPAR
Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6, 12 and 24 Months
Percentage of CSBPARTreatment ATreatment B
CSBPAR at 6 Months7.7 (0.9 to 25.1)9.4 (2.0 to 25.0)
CSBPAR at 12 months11.5 (2.4 to 30.2)12.5 (3.5 to 29.0)
CSBPAR at 24 Months15.4 (4.4 to 34.9)12.5 (3.5 to 29.0)
Statistical analysis
  • Treatment A vs Treatment B · Incidence of change: -1.7 · 95% CI -18.9 to 16.7
  • Treatment A vs Treatment B · Incidence of change: -1.0 · 95% CI -19.2 to 18.9
  • Treatment A vs Treatment B · Incidence of change: 2.9 · 95% CI -16.1 to 23.9
SecondaryTime to Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR).

Time to Clinically suspected biopsy proven acute rejection

Time frame:
Up to 24 Months
Reported as:
Mean · Months
Time to Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR).
MonthsTreatment ATreatment B
Time to Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR).NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With BANFF Grade by Severity Grades. BANFF Type (Grade) for Acute/Active Rejection

Treatment differences in the severity grades to treat all episodes of CSBPAR at 6, 12, and 24 months post-transplant. Type 1A - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>4 mononuclear cells/Tubular cross section or group of 10 Tubular cell). Type 1B - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>10 mononuclear cells/Tubular cross section or group of 10 Tubular cell).Type 2A - Cases with mild to moderate intimal arteritis.Type 2B - Cases with severe intimal arteritis comprising \>25% of the luminal area. Type 3 - Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (v3 with accompanying lymphocytic inflammation)

Time frame:
At 6, 12 and 24 Months
Reported as:
Number · Percentage of Participants
Percentage of Participants With BANFF Grade by Severity Grades. BANFF Type (Grade) for Acute/Active Rejection
Percentage of ParticipantsTreatment ATreatment B
6 Months: Mild Acute (1A)3.80
6 Months: Mild Acute (1B)03.1
6 Months: Moderate Acute (2A)7.76.3
6 Months: Moderate Acute (2B)00
6 Months: Severe Acute00
12 Months: Mild Acute (1A)7.73.1
12 Months: Mild Acute (1B)03.1
12 Months: Moderate Acute (2A)7.76.3
12 Months: Moderate Acute (2B)00
12 Months: Severe Acute00
24 Months: Mild Acute (1A)11.53.1
24 Months: Mild Acute (1B)03.1
24 Months: Moderate Acute (2A)7.76.3
24 Months: Moderate Acute (2B)00
24 Months: Severe Acute00
SecondaryTreatment Differences in Therapeutic Modalities

Treatment Received for Biopsy Proven Acute Rejection (Banff Grade IA or Higher), or Humoral (Antibody Mediated) Rejection Treatment regimen: Categorical analysis of CSBPAR episodes by treatment received.

Time frame:
at 6, 12 and 24 Months
Reported as:
Number · Percentage of participants with CSBPARs
Treatment Differences in Therapeutic Modalities
Percentage of participants with CSBPARsTreatment ATreatment B
Corticosteroids (6 months)7.79.4
Lymphocyte depleting agent (6 months)06.3
Plasmapheresis (6 months)00
IVIG (6 months)03.1
Rituximab (6 months)00
Corticosteroids (12 months)15.412.5
Lymphocyte depleting agent (12 months)3.86.3
Plasmapheresis (12 months)00
IVIG (12 months)03.1
Rituximab (12 months)00
Corticosteroids (24 months)19.212.5
Lymphocyte depleting agent (24 months)3.86.3
Plasmapheresis (24 months)00
IVIG (24 months)03.1
Rituximab (24 months)00
SecondaryNumber of Participants Who Survive With a Functioning Graft

Number of all participants who survive with a functioning graft at 6, 12 and 24 months post transplant

Time frame:
At 6, 12 and 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Survive With a Functioning Graft
ParticipantsTreatment ATreatment B
At 6 Months2531
At 12 Months2531
At 24 Months2531
SecondaryNumber of Participants Deaths Post Transplant

Number of participant deaths at 6, 12 and 24 months post transplant

Time frame:
up to 24 months
Reported as:
Count of participants · Participants
Number of Participants Deaths Post Transplant
ParticipantsTreatment ATreatment B
At 6 Months00
At 12 Months00
At 24 Months00
SecondaryNumber of Participants Who Experience Graft Loss Post Transplant

Number of all participants who experience graft loss at 6, 12 and 24 months post transplant

Time frame:
At 6, 12 and 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience Graft Loss Post Transplant
ParticipantsTreatment ATreatment B
At 6 Months11
At 12 Months11
At 24 Months11
SecondaryTime to Event: Graft Loss and Death

The Number of days to participant Graft Loss and death for any reason

Time frame:
Up to 728 Days
Reported as:
Number · Days
Time to Event: Graft Loss and Death
DaysTreatment ATreatment B
Graft Loss1072
SecondaryAbsolute Calculated Glomerular Filtration Rate (cGFR): Mean

Absolute (mean and median) cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula

Time frame:
Up 24 Months post-transplant
Reported as:
Mean · mL/min/1.73 m^2
Absolute Calculated Glomerular Filtration Rate (cGFR): Mean
mL/min/1.73 m^2Treatment ATreatment B
At 3 Months69.2 (60.2 to 78.3)62.2 (55.3 to 69.1)
At 6 Months66.0 (55.8 to 76.2)63.9 (56.2 to 71.5)
At 12 Months66.2 (56.9 to 75.4)62.0 (53.4 to 70.6)
At 24 Months71.8 (62.5 to 81.0)68.7 (59.2 to 78.2)
SecondaryMedian Calculated Glomerular Filtration Rate (cGFR)

Median cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula

Time frame:
Up 24 Months post-transplant
Reported as:
Median · mL/min/1.73 m^2
Median Calculated Glomerular Filtration Rate (cGFR)
mL/min/1.73 m^2Treatment ATreatment B
At 3 Months64.0 (52.0 to 80.0)62.0 (55.0 to 79.0)
At 6 Months64.0 (56.0 to 79.0)67.0 (55.0 to 75.0)
At 12 Months66.0 (58.0 to 77.0)62.5 (47.5 to 74.0)
At 24 Months73.5 (59.5 to 84.5)68.0 (56.0 to 82.0)
SecondaryMean Change From Month 3 in cGFR

The mean change from Month 3 cGFR at 3, 6, 12 and 24 months post-transplant

Time frame:
Up 24 Months post-transplant
Reported as:
Mean · mL/min/1.73 m^2
Mean Change From Month 3 in cGFR
mL/min/1.73 m^2Treatment ATreatment B
At 3 Months0 (0 to 0)0 (0 to 0)
At 6 Months-3.2 (-10.9 to 4.5)2.8 (-0.2 to 5.8)
At 12 Months-3.1 (-12.6 to 6.5)1.4 (-3.3 to 6.0)
At 24 Months3.1 (-4.2 to 10.4)6.3 (-0.6 to 13.2)
SecondaryUrine Protein Creatinine Ratio (UPr/Cr)

Urine protein to creatinine ratio (UPr/Cr) at 3, 6, 12 and 24 months post-transplant.

Time frame:
Up 24 Months post-transplant
Reported as:
Mean · mg Protein/mg Creatinine
Urine Protein Creatinine Ratio (UPr/Cr)
mg Protein/mg CreatinineTreatment ATreatment B
At 3 Months0.3146 (0.1985 to 0.4307)0.1412 (0.1097 to 0.1726)
At 6 Months0.3896 (0.2326 to 0.5466)0.1461 (0.1203 to 0.1720)
At 12 Months0.2835 (0.1648 to 0.4021)0.1849 (0.1041 to 0.2658)
At 24 Months0.3940 (0.2199 to 0.5680)0.1685 (0.1174 to 0.2195)
SecondaryPercentage of Participants With Donor Specific Anti-HLA Antibodies (DSA)

Percentage of participants with, and titers of pre-existing (pre-transplant) DSA on Day 1 (pre-transplant, pre-dose), and at Months 12 and 24 posttransplant

Time frame:
Up to 24 Months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Donor Specific Anti-HLA Antibodies (DSA)
Percentage of ParticipantsTreatment ATreatment B
Baseline Class 1 DSA100
Baseline Class 2 DSA00
Baseline Both Class 1 and 2 DSA00
12 Month Class 1 DSA8.000
12 Month Class 2 DSA03.03
12 Month Both Class 1 and 2 DSA00
24 Month Class 1 DSA8.003.03
24 Month Class 2 DSA03.03
24 Month Both Class 1 and 2 DSA00
SecondaryPercentage of Participants With De Novo Donor Specific Anti-HLA Antibodies (DSA)

Characterization of any de novo DSA detected by IgM and IgG subclasses, and by the presence or absence of complement fixing properties.

Time frame:
Up to 24 Months
Reported as:
Number · Percentage
Percentage of Participants With De Novo Donor Specific Anti-HLA Antibodies (DSA)
PercentageTreatment ATreatment B
Baseline Class 1 DSA100
Baseline Class 2 DSA00
Baseline Both Class 1 and 2 DSA00
De Novo 12 Month Class 1 DSA00
De Novo 12 Month Class 2 DSA00
De Novo 12 Month Both Class 1 and 2 DSA00
De Novo 24 Month Class 1 DSA03.45
De Novo 24 Month Class 2 DSA00
De Novo 24 Month Both Class 1 and 2 DSA00
SecondaryPercentage of Participants With Adverse Events (AEs)

Percentage of participants with AEs up to 24 months post-transplant

Time frame:
Up to 24 months Post-Transplant
Reported as:
Number · Percentage of participants with AEs
Percentage of Participants With Adverse Events (AEs)
Percentage of participants with AEsTreatment ATreatment B
Percentage of Participants With Adverse Events (AEs)100.097.0
SecondaryPercentage of Participants With Serious Adverse Events (SAEs)

Percentage of participants with SAEs up to 24 months post-transplant

Time frame:
Up to 24 months Post-Transplant
Reported as:
Number · Percentage of participants with SAEs
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participants with SAEsTreatment ATreatment B
Percentage of Participants With Serious Adverse Events (SAEs)52.060.6
SecondaryPercentage of Participants With Events of Special Interest (ESIs)

Percentage of participants which have one of the following events of special interest: Serious Infections Post-Transplant Lymphoproliferative Disorder (PTLD) Progressive multifocal leukoencephalopathy (PML) Malignancies (Other than PTLD) including non-melanoma skin carcinomas (Malignancies) Tuberculosis Infections Central Nervous System (CNS) Infections Viral Infections Infusion Related reactions within 24 hours since belatacept infusion

Time frame:
Up to 24 Months
Reported as:
Number · Percentage of participants with ESIs
Percentage of Participants With Events of Special Interest (ESIs)
Percentage of participants with ESIsTreatment ATreatment B
Serious Infections1615.2
PTLD4.03.0
PML00
Malignancies4.03.0
TB00
CNS Infections00
Viral Infections00
Infusion Related Reactions10
SecondaryPercentage of Particpants With Laboratory Test Abnormalities (LTAs)

Percentage of participants with laboratory tests with marked laboratory abnormalities

Time frame:
At 24 Months
Reported as:
Number · Percentage of participants
Percentage of Particpants With Laboratory Test Abnormalities (LTAs)
Percentage of participantsTreatment ATreatment B
Hemoglobin (Low)12.06.1
Leukocytes (low)03.0
Lymphocyte (Absolute) (low)84.069.7
Neutrophils (Absolute) (low)03.0
Aspartate Aminotransferase (High)4.00
Creatinine (High)16.03.0
Inorganic Phosphorus (low)24.012.1
Potassium (high)4.00
Sodium (low)4.00
Albumin (low)03.0
Glucose (high)8.012.1
Triglycerides (high)12.00
Uric Acid (high)8.00
SecondaryMean and Mean Change From Baseline in Blood Glucose

Mean fasting blood glucose levels, and mean changes from baseline values at Months 6, 12 and 24 months post- transplant

Time frame:
Up to 24 months
Reported as:
Mean · mg/dL
Mean and Mean Change From Baseline in Blood Glucose
mg/dLTreatment ATreatment B
Mean Value at 6 months107.2 (86.6 to 127.8)107.2 (93.8 to 120.7)
Change from baseline at 6 months4.9 (-5.8 to 15.7)4.8 (-17.6 to 27.2)
Mean Value at 12 months101.1 (85.3 to 117.0)127.5 (99.2 to 155.8)
Change from baseline at 12 months-1.3 (-24.7 to 22.1)20.6 (0.4 to 40.8)
Mean Value at 24 months127.5 (93.7 to 161.4)111.8 (87.1 to 136.5)
Change from baseline at 24 months22.3 (-15.7 to 60.3)15.0 (-3.2 to 33.2)
SecondaryMean and Mean Change From Baseline in Whole Blood HbA1c

Mean whole blood HbA1C concentrations, and mean changes from baseline values at Months 6, 12 and 24 months post-transplant.

Time frame:
Up to 24 months
Reported as:
Mean · mg/dL
Mean and Mean Change From Baseline in Whole Blood HbA1c
mg/dLTreatment ATreatment B
Mean Value at 6 months6.11 (5.47 to 6.75)6.13 (5.44 to 6.82)
Change from baseline at 6 months0.34 (0.06 to 0.62)0.48 (0.04 to 0.91)
Mean Value at 12 months6.18 (5.42 to 6.93)6.21 (5.50 to 6.92)
Change from baseline at 12 months0.47 (-0.00 to 0.95)0.32 (-0.17 to 0.81)
Mean Value at 24 months6.24 (5.27 to 7.20)6.29 (5.38 to 7.20)
Change from baseline at 24 months0.66 (-0.05 to 1.37)0.41 (-0.13 to 0.95)
SecondaryPercentage of Participants With New Onset Diabetes After Transplant

Percentage of participants with New Onset Diabetes After Transplantation (NODAT) at 6, 12, and 24 months post-transplant.

Time frame:
up to 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants With New Onset Diabetes After Transplant
Percentage of participantsTreatment ATreatment B
Up to 6 Months11.5 (2.4 to 30.2)6.3 (0.8 to 20.8)
Up to 12 Months11.5 (2.4 to 30.2)6.3 (0.8 to 20.8)
Up to 24 Months15.4 (4.4 to 34.9)12.5 (3.5 to 29.0)
SecondaryAbsolute Values of Blood Pressure: Mean

Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;

Time frame:
Up to 24 Months
Reported as:
Mean · mmHg
Absolute Values of Blood Pressure: Mean
mmHgTreatment ATreatment B
Diastolic Month 378.7 (74.2 to 83.2)77.7 (74.0 to 81.3)
Systolic Month 3134.2 (126.9 to 141.6)131.0 (124.9 to 137.0)
Diastolic Month 677.4 (73.6 to 81.3)79.4 (76.0 to 82.9)
Systolic Month 6128.1 (121.8 to 134.5)133.0 (127.2 to 138.8)
Diastolic Month 1278.7 (74.6 to 82.9)80.1 (76.4 to 83.8)
Systolic Month 12131.0 (125.6 to 136.4)131.0 (123.4 to 138.7)
Diastolic Month 2478.1 (74.2 to 81.9)78.5 (74.3 to 82.8)
Systolic Month 24130.9 (125.2 to 136.5)131.7 (125.2 to 138.2)
SecondaryAbsolute Values of Blood Pressure: Median

Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;

Time frame:
Up to 24 Months
Reported as:
Median · mmHg
Absolute Values of Blood Pressure: Median
mmHgTreatment ATreatment B
Diastolic Month 378.5 (70.0 to 88.0)80.0 (70.0 to 84.0)
Systolic Month 3135.5 (127.0 to 144.0)131.0 (122.0 to 138.0)
Diastolic Month 675.5 (70.5 to 83.0)80.0 (71.0 to 85.5)
Systolic Month 6127.0 (114.5 to 136.5)131.0 (124.0 to 142.5)
Diastolic Month 1277.0 (71.5 to 86.0)81.0 (72.0 to 88.0)
Systolic Month 12130.0 (119.0 to 142.0)126.0 (115.0 to 146.0)
Diastolic Month 2478.0 (71.0 to 86.0)79.0 (69.5 to 85.0)
Systolic Month 24130.0 (122.0 to 142.0)130.0 (121.5 to 139.0)
SecondaryMean Changes From Baseline Values for Blood Pressure

Mean changes from baseline values for SBP and DBP at 6, 12 and 24 months post-transplant

Time frame:
Up to 24 Months
Reported as:
Mean · mmHg
Mean Changes From Baseline Values for Blood Pressure
mmHgTreatment ATreatment B
Diastolic Month 61.0 (-4.7 to 6.7)4.8 (-1.2 to 10.8)
Systolic Month 6-4.0 (-13.9 to 5.9)-0.7 (-10.0 to 8.7)
Diastolic Month 122.3 (-4.0 to 8.6)5.4 (-1.0 to 11.7)
Systolic Month 12-1.1 (-9.6 to 7.4)-3.2 (-14.7 to 8.3)
Diastolic Month 240.9 (-5.5 to 7.3)2.1 (-3.9 to 8.1)
Systolic Month 24-2.3 (-12.2 to 7.6)-4.2 (-14.4 to 6.0)
SecondaryAbsolute Values of Fasting Lipid Values: Mean

Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)

Time frame:
Up to 24 Months
Reported as:
Mean · mg/dL
Absolute Values of Fasting Lipid Values: Mean
mg/dLTreatment ATreatment B
TC Month 3181.2 (157.8 to 204.7)174.4 (154.8 to 194.1)
TC Month 6197.7 (177.9 to 217.4)175 (158.8 to 191.6)
TC Month 12189.0 (171.7 to 206.3)169.9 (153.8 to 186.0)
TC Month 24193.2 (172.1 to 214.2)168.2 (152.9 to 183.4)
HDL Month 350.6 (43.5 to 57.6)50.4 (43.9 to 56.9)
HDL Month 646.4 (41.3 to 51.5)53.9 (45.9 to 61.8)
HDL Month 1249.4 (44.0 to 54.8)49.6 (42.5 to 56.6)
HDL Month 2450.1 (44.7 to 55.5)51.3 (43.0 to 59.6)
LDL Month 396.9 (77.9 to 115.9)96.5 (80.3 to 112.6)
LDL Month 6115.2 (98.1 to 132.3)93.7 (79.2 to 108.2)
LDL Month 12107.5 (92.8 to 122.2)88.0 (74.3 to 101.8)
LDL Month 2497.9 (81.6 to 114.2)91.5 (75.4 to 107.6)
TG Month 3171.6 (118.1 to 225.0)137.8 (106.6 to 168.9)
TG Month 6180.0 (140.2 to 219.7)138.3 (108.0 to 168.5)
TG Month 12162.4 (132.2 to 192.6)161.3 (126.4 to 196.1)
TG Month 24263.4 (131.2 to 395.5)145.0 (99.8 to 190.2)
SecondaryAbsolute Values of Fasting Lipid Values: Median

Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)

Time frame:
Up to 24 Months
Reported as:
Median · mg/dL
Absolute Values of Fasting Lipid Values: Median
mg/dLTreatment ATreatment B
TC Month 3167.0 (160.0 to 213.0)173.0 (146.0 to 197.0)
TC Month 6187.0 (170.5 to 226.5)178.0 (146.0 to 199.0)
TC Month 12184.0 (166.0 to 213.0)171.5 (146.5 to 193.5)
TC Month 24193.0 (166.0 to 206.0)166.0 (137.0 to 201.0)
HDL Month 345.0 (39.0 to 62.0)49.0 (38.0 to 63.0)
HDL Month 645.5 (39.0 to 51.0)49.0 (37.0 to 68.0)
HDL Month 1250.0 (40.0 to 58.0)47.0 (37.0 to 61.0)
HDL Month 2449.0 (43.0 to 58.0)49.0 (35.0 to 71.0)
LDL Month 389.0 (74.0 to 127.0)95.0 (75.0 to 116.0)
LDL Month 699.5 (85.5 to 143.0)100.0 (66.0 to 115.0)
LDL Month 12104.0 (85.0 to 128.0)91.5 (65.0 to 109.0)
LDL Month 24103.5 (74.0 to 121.0)86.0 (70.0 to 119.0)
TG Month 3147.0 (107.0 to 195.0)128.0 (81.0 to 174.0)
TG Month 6157.5 (113.5 to 245.5)126.0 (85.0 to 194.0)
TG Month 12154.0 (100.0 to 230.0)130.0 (106.0 to 202.0)
TG Month 24159.0 (137.0 to 284.0)114.0 (80.0 to 174.0)
SecondaryMean Changes From Baseline Values of Lipid Values

Mean changes from baseline values in the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)

Time frame:
at months 12 and 24
Reported as:
Mean · mg/dL
Mean Changes From Baseline Values of Lipid Values
mg/dLTreatment ATreatment B
TC Month 1225.7 (3.5 to 47.9)-2.8 (-41.5 to 35.8)
TC Month 2426.6 (4.0 to 49.1)10.0 (-9.9 to 29.9)
HDL Month 125.4 (-0.3 to 11.0)1.9 (-3.7 to 7.5)
HDL Month 246.2 (0.7 to 11.6)4.8 (-2.2 to 11.9)
LDL Month 1225.7 (7.9 to 43.4)10.8 (-10.8 to 32.4)
LDL Month 2417.4 (0.0 to 34.7)15.7 (-4.4 to 35.7)
TG Month 123.3 (-26.0 to 32.5)-86.1 (-288.9 to 116.7)
TG Month 24106.8 (-32.6 to 246.2)-13.6 (-73.8 to 46.5)

Adverse events

Collected over Up to 24 months after last treatment dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BELA+EVL0/25 (0%)13/25 (52%)25/25 (100%)
TAC+MMF0/33 (0%)20/33 (60.6%)30/33 (90.9%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventBELA+EVLTAC+MMF
NeutropeniaBlood and lymphatic system disorders0/254/33
Urinary tract infectionInfections and infestations3/250/33
Blood creatinine increasedInvestigations1/253/33
Cholecystitis acuteHepatobiliary disorders2/250/33
Febrile neutropeniaBlood and lymphatic system disorders0/252/33
Acute kidney injuryRenal and urinary disorders0/252/33
AnaemiaBlood and lymphatic system disorders1/251/33
PancytopeniaBlood and lymphatic system disorders1/250/33
Atrial fibrillationCardiac disorders1/251/33
AscitesGastrointestinal disorders1/250/33
Most frequent other events
Showing 10 of 93
Most frequent other events
EventBELA+EVLTAC+MMF
Mouth ulcerationGastrointestinal disorders10/250/33
NauseaGastrointestinal disorders5/2513/33
HypophosphataemiaMetabolism and nutrition disorders9/258/33
HyperkalaemiaMetabolism and nutrition disorders1/2511/33
LeukopeniaBlood and lymphatic system disorders8/257/33
ConstipationGastrointestinal disorders5/2510/33
DiarrhoeaGastrointestinal disorders4/2510/33
HypokalaemiaMetabolism and nutrition disorders7/253/33
HypomagnesaemiaMetabolism and nutrition disorders2/258/33
HypertensionVascular disorders6/258/33

Baseline characteristics

Randomized, Transplanted and Treated Population (ITT)

Age, Continuous
Age, Continuous(Years)Treatment ATreatment BTotal
Mean51.7 ± 12.850.8 ± 10.951.2 ± 11.7
Age, Customized
Age, Customized(Participants)Treatment ATreatment BTotal
< 65222850
≥ 65448
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ATreatment BTotal
Female5914
Male212344
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment ATreatment BTotal
American Indian or Alaska Native000
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American369
White232144
More than one race000
Unknown or Not Reported022
08

Study locations

20 sites
  • California Institute Of Renal Research
    San Diego, California 92123, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Yale University
    New Haven, Connecticut 06519, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Emory Univeristy
    Atlanta, Georgia 30322, United States
  • University Of Illinois
    Chicago, Illinois 60612, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • Wake Forest University School Of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Central PA Transplant Foundation
    Harrisburg, Pennsylvania 17104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Virginia
    Charlottesville, Virginia 22908-0709, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Swedish Medical Center - Swedish Colon and Rectal Clinic - First Hill (Northwest Colon and Rectal Cl
    Seattle, Washington 98104, United States
  • Sanatorio Parque S.A.
    Rosario, Santa Fe 2000, Argentina
  • Clinica Privada Velez Sarsfield
    Cordoba, 5016, Argentina
  • Clinica De Nefrologia, Urologia Y Enf. Cardiovasculares
    Sante Fe, 3000, Argentina
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in May 2019, 40 months.

Results were first posted in Jun 2021, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2014
First posted
May 13, 2014
StartActual
Dec 31, 2015
Primary completionActual
May 2, 2019
CompletionActual
May 2, 2019
Results first posted
Jun 22, 2021
Last update
Jun 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02137239
Responsible party
Sponsor
First posted
May 13, 2014
Start date
Dec 31, 2015
Primary completion
May 2, 2019
Completion
May 2, 2019
Results posted
Jun 22, 2021
Last update
Jun 22, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion